Antithrombotic amongst NICE technology appraisals for July

Bivalirudin, intravitreal dexamethasone and retigabine have been appraised by NICE | SCIENCE PHOTO LIBRARY
Bivalirudin, intravitreal dexamethasone and retigabine have been appraised by NICE | SCIENCE PHOTO LIBRARY
The technology appraisals issued by NICE in July included an antiepileptic, an antithrombotic and an intravitreal implant.

Bivalirudin in combination with aspirin and clopidogrel has been recommended for the treatment of patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Dexamethasone intravitreal implants have been approved for the treatment of macular oedema secondary to central retinal vein occlusion. It is also recommended for macular oedema following branch retinal vein occlusion when treatment with laser photocoagulation:
•    has not been beneficial or
•    is considered unsuitable owing to the extent of macular haemorrhage.

Retigabine has been recommended by NICE as an option for the adjunctive treatment of partial onset seizures with or without secondary generalisation in adults with epilepsy, only when previous treatment with carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate and topiramate has not provided an adequate response or has not been tolerated.


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases